Florence Herschke

Florence Herschke

Auto-generated profile, based on publicly available information

Florence Herschke

ExeVir Bio BV, Ghent, Belgium

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DMDavid McGowan
David McGowan
FHFlorence Herschke
Florence Herschke
FPFrederik Pauwels
Frederik Pauwels
BSBart Stoops
Bart Stoops
SLStefaan Last
Stefaan Last
PRPierre Raboisson
Pierre Raboisson

1 December 2021 in Antiviral Research
Verified
Journal Article
Open access
FHFlorence Herschke
Florence Herschke
CLChris Li
Chris Li
RZRen Zhu
Ren Zhu
QHQinglin Han
Qinglin Han
QWQun Wu
Qun Wu
ACAn De Creus
An De Creus
JNJ-64794964 (JNJ-4964/AL-034/TQ-A3334), an oral toll-like receptor 7 agonist, is being investigated for the treatment of chronic hepatitis B (CHB), a condition with a high unmet medical need. The anti-hepatitis B (HBV) activity of JNJ-4964 was assessed preclinically in an adeno-associated virus vector expressing HBV (AAV/HBV) mouse model. Mice were treated orally with 2, 6 or 20 mg/kg of JNJ-4964 once-per-week for 12 weeks and then followed up for 4 weeks. At 6 mg/kg, a partial decrease in plasma HBV-DNA and plasma hepatitis B surface antigen (HBsAg) was observed, and anti-HBs antibodies and HBsAg-specific T cells were observed in 1/8 animals. At 20 mg/kg, plasma HBV-DNA and HBsAg levels were undetectable for all animals 3 weeks after start of treatment, with no rebound observed 4 weeks after JNJ-4964 treatment was stopped. High anti-HBs antibody levels were observed until 4 weeks after JNJ-4964 treatment was stopped. In parallel, HBsAg-specific immunoglobulin G-producing B cells and interferon-gamma-producing CD4+ T cells were detected in the spleen. In 2/4 animals, liver HBV-DNA and HBV-RNA levels and liver hepatitis B core antigen expression dropped 4 weeks after JNJ-4964 treatment-stop. In these animals, HBsAg-specific CD8+ T cells were detectable. Throughout the study, normal levels of alanine aminotransferase were observed, with no hepatocyte cell death (end of treatment and 4 weeks later) and minimal infiltrations of B and T cells into the liver, suggesting induction of cytokine-mediated, non-cytolytic mechanisms.

14 July 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DMDavid C. McGowan
David C. McGowan
FHFlorence Herschke
Florence Herschke
FPFrederik Pauwels
Frederik Pauwels
BSBart Stoops
Bart Stoops
ISIlham Smyej
Ilham Smyej
PRPierre Raboisson
Pierre Raboisson

19 May 2024 in Antiviral Research
Verified
Journal Article
Open access
BBBrecht Bonneux
Brecht Bonneux
ASAfzaal Shareef
Afzaal Shareef
STSergey Tcherniuk
Sergey Tcherniuk
BABrandon Anson
Brandon Anson
SBSuzanne de Bruyn
Suzanne de Bruyn
FHFlorence Herschke
Florence Herschke
Respiratory syncytial virus (RSV) can cause pulmonary complications in infants, elderly and immunocompromised patients. While two vaccines and two prophylactic monoclonal antibodies are now available, treatment options are still needed. JNJ-7184 is a non-nucleoside inhibitor of the RSV-Large (L) polymerase, displaying potent inhibition of both RSV-A and -B strains. Resistance selection and hydrogen-deuterium exchange experiments suggest JNJ-7184 binds RSV-L in the connector domain. JNJ-7184 prevents RSV replication and transcription by inhibiting initiation or early elongation. JNJ-7184 is effective in air-liquid interface cultures and therapeutically in neonatal lambs, acting to drastically reverse the appearance of lung pathology.

18 May 2023 in Antiviral Therapy
Verified
Journal Article
Open access
WPWim Pierson
Wim Pierson
MTMarianne Tuefferd
Marianne Tuefferd
FHFlorence Herschke
Florence Herschke
LSLeen Slaets
Leen Slaets
MCMarjolein Crabbe
Marjolein Crabbe
ACAn De Creus
An De Creus
Background: Chronic hepatitis B (CHB) is responsible for major disease burden worldwide. However, the number of available therapies is limited; cure remains an elusive goal. JNJ-64794964 (JNJ-4964) is an oral toll-like receptor-7 (TLR7) agonist being evaluated for the treatment of CHB. Here, we investigated the capacity of JNJ-4964 to induce transcriptomic and immune cell changes in peripheral blood in healthy volunteers. Methods: Peripheral blood was collected in the JNJ-4964 first-in-human phase 1 trial at multiple time points to assess transcriptomics and changes in frequency and phenotype of peripheral-blood mononuclear cells. Correlation of changes to JNJ-4964 exposure (C max ) and changes in cytokine levels (C-X-C motif chemokine ligand 10 [CXCL10] and interferon alpha [IFN-α]) were evaluated. Results: Fifty-nine genes, mainly interferon-stimulated genes, were up-regulated between 6 hours and 5 days after JNJ-4964 administration. JNJ-4964 increased frequencies of CD69, CD134, CD137, and/or CD253-expressing natural killer (NK) cells, indicative of NK cell activation. These changes correlated with C max , increase of CXCL10, and induction of IFN-α and were observed at IFN-α levels that are associated with no/acceptable flu-like adverse events. JNJ-4964 administration resulted in increased frequencies of CD86-expressing B cells, indicative of B-cell activation. These changes were predominantly observed at high IFN-α levels, which are associated with flu-like adverse events. Conclusions: JNJ-4964 administration led to changes in transcriptional profiles and immune cell activation phenotype, particularly for NK cells and B cells. Together, these changes could represent a set of biomarkers for the characterization of the immune response in CHB patients receiving TLR7 agonists.

9 February 2026 in Antiviral Research
Verified
Journal Article
Open access
FTFrancesca Toselli
Francesca Toselli
SJSofie Jacobs
Sofie Jacobs
ESEls Scheers
Els Scheers
TJTom Jacobs
Tom Jacobs
JDJordi Doijen
Jordi Doijen
FHFlorence Herschke
Florence Herschke
The coronavirus disease 2019 (COVID-19) pandemic, driven by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has highlighted the urgent need for effective therapeutics, particularly as limitations of existing antiviral treatments persist. Establishing the proper strategy to set target concentrations for human dose projection is essential for any novel drug development project. In this study, we investigated the translatability of various preclinical models, specifically in vitro A549-hACE2 cells and air-liquid interface human nasal epithelial cultures, and in vivo Syrian golden hamsters and K18-hACE2 transgenic mice, using 3-chymotrypsin-like protease (3CLpro) inhibitors as model direct-acting antivirals. We assessed the minimal efficacious concentrations in these models of both ensitrelvir (ETV) and nirmatrelvir (NTV) co-dosed with ritonavir (Paxlovid) and compared this to clinical human data. Notably, in vitro models and the K18-hACE2 mice proved to be the most predictive for human efficacious exposures. Interestingly, lower efficacious exposures were needed in the more severe K18-hACE2 mouse model than in the Syrian golden hamster model for mild infection. Overall, we recommend applying a factor of 4-fold to the in vitro 90% effective concentration (EC90) for a conservative estimate of human efficacious exposure and recommend validation using K18-hACE2 mice. These insights are critical for guiding the development of effective SARS-CoV-2 therapeutics and optimizing clinical trial design.